All In Biotech

Drug Trial Radar · NCT06047080

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,130 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,130

Actual

Start

Sep 18, 2023

Primary completion

Oct 1, 2027

Study completion Oct 30, 2030

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Sep 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma (LBCL).

Conditions

  • Large B-Cell Lymphoma

Interventions

  • GlofitamabDrug

    Participants will receive intravenous (IV) glofitamab

  • Polatuzumab vedotinDrug

    Participants will receive IV polatuzumab vedotin in combination with R-CHP

  • RituximabDrug

    Participants will receive IV rituximab

  • CyclophosphamideDrug

    Participants will receive cyclophosphamide as part of CHP chemotherapy

  • DoxorubicinDrug

    Participants will receive IV doxorubicin

  • PrednisoneDrug

    Participants will receive oral prednisone as part of CHP chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) as determined by Independent Review Facility (IRF)Time frame: From randomization to the first occurrence of disease progression or relapse, or death due to any cause, whichever occurs first (up to approximately 65 months)

Locations

229 sites in 21 countries. Site status is shown where the registry gives one.

  • Alaska Oncology & Hematology, LLC

    Anchorage, Alaska

  • Kaiser Permanente - Anaheim (E. La Palma)

    Anaheim, California

  • University of California, San Francisco-Fresno

    Clovis, California

  • City of Hope National Medical Center

    Duarte, California

  • City of Hope - Lennar Foundation Cancer Center

    Irvine, California

  • Valkyrie Clinical Trials

    Los Angeles, California

  • UCLA Jonsson Comprehensive Cancer Center

    Los Angeles, California

  • Kaiser Permanente - Roseville

    Roseville, California

  • Kaiser Permanente - Santa Clara

    Santa Clara, California

  • Stanford Univ School of Med

    Stanford, California

  • Kaiser Permanente Medical Ctr

    Vallejo, California

  • University of Colorado Cancer Center

    Aurora, Colorado

  • Rocky Mountain Cancer Center - Denver

    Littleton, Colorado

  • Yale University School Of Medicine

    New Haven, Connecticut

  • Medstar Franklin Square Medical Center

    Washington D.C., District of Columbia

  • Miami Cancer Institute of Baptist Health, Inc.

    Miami, Florida

  • Memorial Cancer Institute at Memorial West

    Pembroke Pines, Florida

  • Hawaii Cancer Care

    Honolulu, Hawaii

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University

    Chicago, Illinois

  • Illinois Cancer Care

    Peoria, Illinois

  • Springfield Clinic

    Springfield, Illinois

  • University of Iowa

    Iowa City, Iowa

  • Ascension Via Christi Research

    Wichita, Kansas

  • Ochsner Medical Center

    New Orleans, Louisiana

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Boston Medical Center

    Boston, Massachusetts

  • Henry Ford Health System

    Novi, Michigan

  • M Health Fairview University of Minnesota Medical Center

    Minneapolis, Minnesota

  • St. Luke's Hospital

    Chesterfield, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • NYU Langone Hospital?Brooklyn

    Brooklyn, New York

  • NYU Long Island Hospital

    Mineola, New York

  • New York University Medical Center PRIME

    New York, New York

  • Memorial Sloan Kettering Cancer Center David H Koch Center for Cancer Care

    New York, New York

  • Weill Cornell Medical College-New York Presbyterian Hospital

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • North Shore Hematology Oncology Association PC

    Shirley, New York

  • Montefiore Medical Center

    The Bronx, New York

Showing 40 of 229 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.